According to the official WeChat account of China Bio-official WeChat, on July 6, China Institute of Biological Products of Sinopharm Group (hereinafter referred to as "Sinopharm Group Zhongsheng Beijing Institute") was approved by the relevant departments of the joint prevention and control mechanism of the State Council, and it was urgently used among people aged 3- 17. This means that China COVID-19 inactivated vaccine has been officially approved for emergency use in this age group.
According to the report of China Biology, COVID-19 vaccine of Sinopharm Group has completed the phase I/II clinical trial in Henan at the age of 3- 17.
Previously reported:
On June 1 1, Cui Gang, the second-level inspector of National Health Commission CDC, revealed at the press conference of the joint prevention and control mechanism in the State Council that the relevant departments had approved the emergency use of COVID-19 inactivated vaccine for people aged 3- 17.
In March this year, Kexing Holding Biotechnology Co., Ltd. also released the clinical research data of inactivated vaccine for minors in COVID-19. The preliminary analysis results showed that the safety and immunogenicity of Clover COVID-19 vaccine in minors aged 3- 17 were good, which was obviously superior to that of adults and the elderly, suggesting that COVID-19 vaccine may be superior to adults and the elderly in protecting minors;
In 3- 1 1 year-old children, the low dose vaccine showed good immunogenicity, suggesting that children can choose a lower dose vaccine for vaccination.
The above contents refer to China Economic Net-What is the difference between vaccination for teenagers and adults? What is the protective effect? The authoritative interpretation of experts has come.